These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33534958)

  • 41. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction.
    Yang Z; Tian R; Zhang XJ; Cai J; She ZG; Li H
    Front Cardiovasc Med; 2022; 9():1120085. PubMed ID: 36712249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-alcoholic fatty liver disease.
    Powell EE; Wong VW; Rinella M
    Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
    Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
    J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study.
    Iorio A; Senni M; Barbati G; Greene SJ; Poli S; Zambon E; Di Nora C; Cioffi G; Tarantini L; Gavazzi A; Sinagra G; Di Lenarda A
    Eur J Heart Fail; 2018 Sep; 20(9):1257-1266. PubMed ID: 29917301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
    Belfort-DeAguiar R; Lomonaco R; Cusi K
    J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options.
    Grander C; Grabherr F; Tilg H
    Cardiovasc Res; 2023 Aug; 119(9):1787-1798. PubMed ID: 37364164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes.
    Monda VM; Gentile S; Porcellati F; Satta E; Fucili A; Monesi M; Strollo F
    Adv Ther; 2022 Nov; 39(11):4837-4846. PubMed ID: 36112311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NAFLD and cardiovascular diseases: a clinical review.
    Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
    Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
    Gehlken C; Screever EM; Suthahar N; van der Meer P; Westenbrink BD; Coster JE; Van Veldhuisen DJ; de Boer RA; Meijers WC
    ESC Heart Fail; 2021 Aug; 8(4):2458-2466. PubMed ID: 34085774
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Progress in the Management of NAFLD/NASH].
    Aizawa Y
    Rinsho Byori; 2016 Jul; 64(7):797-805. PubMed ID: 30695468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
    Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-Alcoholic Fatty Liver Disease Is Associated with Impairment of Ejection Fraction Among Individuals with Obesity Undergoing Bariatric Surgery: Results of a Cross-Sectional Study.
    de Freitas Diniz TB; de Jesus RN; Jimenez LS; Pareja JC; Chaim EA; Cazzo E
    Obes Surg; 2020 Feb; 30(2):456-460. PubMed ID: 31529394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
    J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Study of Correlation between Non Alcoholic Fatty Liver Disease and Carotid Atherosclerosis.
    Sagar A; L R; Farheen SA
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.